Drug Trial Radar · NCT01893138
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Last checked: Nov 19, 2026Latest source record: Jan 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
311
Actual
Start
Nov 21, 2013
Primary completion
Nov 1, 2019
Study completion Nov 10, 2020
Sponsor
- Lead sponsor
- Cook MyoSiteIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo (vehicle) control dose in the treatment of stress urinary incontinence (SUI) in adult female patients.
Conditions
- Stress Urinary Incontinence
Interventions
PlaceboOther
Placebo control is the vehicle solution used for the study product.
IltamiocelBiological
AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day DiaryTime frame: Baseline and 12 months
Locations
29 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona Phoenix Campus
Phoenix, Arizona
The American Association of Female Pelvic Medicine Specialists
Agoura Hills, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Stanford University
Stanford, California
Cleveland Clinic Florida
Weston, Florida
Emory University
Atlanta, Georgia
NorthShore University HealthSystem
Skokie, Illinois
IU Health Physicians Urogynecology
Indianapolis, Indiana
Female Pelvic Medicine & Urogynecology Institute of Michigan
Grand Rapids, Michigan
Mercy Health Saint Mary's Campus
Grand Rapids, Michigan
William Beaumont Hospital
Royal Oak, Michigan
NYU Urology Associates
New York, New York
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York
Montefiore Medical Center
The Bronx, New York
McKay Urology
Charlotte, North Carolina
The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Greenville Health System
Greenville, South Carolina
Sanford Female Pelvic Medicine and Reconstructive Surgery Clinic
Sioux Falls, South Dakota
Vanderbilt University Medical Center
Nashville, Tennessee
Methodist Urology Associates
Houston, Texas
Inova Fairfax Hospital
Falls Church, Virginia
Benaroya Research Institute at Virginia Mason
Seattle, Washington
University Hospital Leuven
Leuven, Belgium
Universitätsklinikum Essen
Essen, Germany
Praxisklinik Urologie Rhein-Ruhr (PUR/R)
Mülheim, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.